Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

A Phase 1, Open-Label, Dose-Escalation Study of a CDK9 Inhibitor, PRT2527, in Adult Patients With Advanced Solid Tumors: An Updated Analysis

Friday, October 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a Phase 1, open-label, dose-escalation study of PRT2527, a CDK9 inhibitor, in adult patients with advanced solid tumors. This updated analysis includes contributions from multiple experts in the field, highlighting the potential of PRT2527 in oncology. The study aims to evaluate the safety and efficacy of the drug in a challenging patient population.
Price reaction · baseline $2.32 (2023-10-19 close) · hit pre-market · 4 other PRLD headline(s) in the window, move may be shared
day 0 close · peak
+3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study is focused on a promising CDK9 inhibitor, PRT2527.
  • It targets advanced solid tumors, addressing a critical area in oncology.
  • The open-label design allows for real-time data collection and patient feedback.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Manish R. Patel, Atrayee Basu-Mallick, Filemon Dela Cruz, Douglas Orr, Alex Spira, Guru P. Sonpavde, Pooja Ghatalia, Christine Lihou, Neelesh Sharma, Peggy Scherle, Jennifer Xavier, William Sun, Sri Sahasranaman, Jason T. Henry

Frequently Asked Questions

What is the focus of the study on PRT2527?

The study focuses on PRT2527, a CDK9 inhibitor, for treating advanced solid tumors.

What type of study design is used for PRT2527?

The study utilizes an open-label, dose-escalation design.

Who are the contributors to the study?

The study includes contributions from multiple oncology experts.

What is the goal of the PRT2527 study?

The goal is to evaluate the safety and efficacy of PRT2527 in patients.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT2527 CDK9 inhibitor advanced solid tumors Phase 1 study oncology
Last updated: Oct 20, 2023

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →